Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma

By sjmartinez • April 10, 2024

Gleason L, Afifi L, Banner L, Talasila S, Joffe D, Bhatti S, Alpdogan O, Porcu P, Nikbakht N. Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma. Mol Clin Oncol. 2024 Mar 19;20(5):35. doi: 10.3892/mco.2024.2733. PMID: 38596625; PMCID: PMC11002836.

Tags: anaplastic large cell, anaplastic lymphoma kinase, CD30+, Dermatology, lymphoma, primary cutaneous anaplastic large cell lymphoma, Publications, Resident, systemic anaplastic large cell lymphoma

ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype

Assan F, Tragin M, Marella S, Lipecka J, Roger K, Zarhrate M, Bondet V, Nguyen V, Akroun F, Nitschké P, Guerrera IC, Bole C, Izmiryan[...]

A practical inflammatory blood-cell marker for cardiovascular risk stratification in psoriasis: Development of the Platelet-Leukocyte Adjusted Cardiovascular (PLAC) score

Cortes JA, Aflatooni S, Ure A, Palma G, Johnsen N, Smart K, Nong Y, Armstrong AW. A practical inflammatory blood-cell marker for cardiovascular risk stratification[...]

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

Stein Gold L, Armstrong AW, Soung J, Vender RB, González Cantero Á, Hoffmann M, Guenthner ST, Hong HC, Murrell DF, Song EJ, Kircik L, Augustin[...]